Global Bacterial Conjunctivitis Market By Drug Class (Fluoroquinolones, Aminoglycosides, Macrolides and Others) - Growth, Future Prospects & Competitive Analysis, 2017- 2025

The drivers responsible for the deep market penetration of drugs utilized for treatment of bacterial conjunctivitis are the rising prevalence of bacterial conjunctivitis, water and air pollution and lack of personal hygiene. Technological advancement in the drug development with effective drug concentration such as ISV-405 (Azithromycin 2.0%) which has resulted into immediate relief as the dose required is minimum and hence less drug related adverse events. A strong limitation of bacterial conjunctivitis is the number of parameters that can be detected are very limited, and the overlapping of symptoms of adenoviral and bacterial conjunctivitis is ambiguous resulting into ineffective dosage regimen.

For the purpose of this study, the various products studied includes fluoroquinolones, aminoglycosides, macrolides and others. The fluoroquinolones are classified as (Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Gatifloxacin, and Besifloxacin) Aminoglycosides are further classified as (Tobramycin, Gentamycin). Macrolides are categorized as (Erythromycin and Azithromycin). Others consists of (Phenicols, Glycolipopeptides and Cyclic Polypeptides). Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global bacterial conjunctivitis market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year. 

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global bacterial conjunctivitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global bacterial conjunctivitis market. The major players in bacterial conjunctivitis market are Actavis Plc., Akorn, Inc., Bayer AG, F. Hoffman La-Roche Ltd., InSite Vision Incorporated, Merck & Co. Inc., Novartis AG, Perrigo Company Plc., Pfizer, Inc., Santen Pharmaceutical Co. Ltd.

Bacterial Conjunctivitis Market

Based on drug class, the global bacterial conjunctivitis market is categorized into

  • Fluoroquinolones
    • Ciprofloxacin
    • Ofloxacin
    • Levofloxacin
    • Moxifloxacin
    • Gatifloxacin
    • Besifloxacin
  • Aminoglycosides
    • Tobramycin
    • Gentamycin
  • Macrolides
    • Erythromycin
    • Azithromycin
  • Others (Phenicols, Glycolipopetides, Cyclic Polypeptides)

Bacterial Conjunctivitis Market

The bacterial conjunctivitis market is driven by factors such as pharmaceutical R&D focusing on treatment of bacterial conjunctivitis, rising public awareness and alliances between pharmaceutical giants and research institutes. In addition, rising prevalence of bacterial conjunctivitis and increasing air and water pollution affecting the eye conjunctiva. In 2016, fluoroquinolones segment held the largest market share chiefly due to factors such as the broad spectrum antimicrobial activity offered by fluoroquinolones against the Gram-positive, Gram-negative and anaerobic organisms. Technological advancement in the drug formulation has rendered current generation fluoroquinolones such as gatifloxacin, moxifloxacin and besifloxacin as first line of treatment. The limitations of this segment throughout the forecast period is the forthcoming patent expiration of blockbuster branded drugs of the fluoroquinolones drug class. Aminoglycosides and macrolides together will be the fastest growing segment throughout the forecast period 2017-2025. Factors contributing to the growth of this segment are increasing incidences of antibiotics related drug resistance in bacterial conjunctivitis patients and technological advancement with effective clinical trials conducted to analyze safety and efficacy related to the drug formulation of antibiotics at different concentration resulting in immediate relief due to faster onset of action. The major players in bacterial conjunctivitis market are Actavis Plc., Akorn, Inc., Bayer AG, F.Hoffman La-Roche Ltd., InSite Vision Incorporated, Merck & Co. Inc., Novartis AG, Perrigo Company Plc., Pfizer, Inc., Santen Pharmaceutical Co., Ltd.

For the purpose of this study, the global bacterial conjunctivitis market is categorized into the following regional and country specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Bacterial Conjunctivitis Market
 

North America was observed to be the largest market for bacterial conjunctivitis in the base year 2016. According to the National Eye Institute, in 2016, about 3 million cases are reported suffering with bacterial conjunctivitis. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of bacterial conjunctivitis, existence of developed research and healthcare institutions and affordable reimbursement scenario. The market growth in Europe is mainly attributed to the rising prevalence of air and water pollution, presence of pharmaceutical giants pioneering in the treatment of bacterial conjunctivitis. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2017-2025. Factors that are anticipated to propel the market growth are increasing disposable income and supportive regulatory environment for bacterial conjunctivitis products. Moreover, factors such as developing health infrastructure, business expansion by pharmaceutical giants in the untapped markets with unmet medical needs are going to fuel the rapid growth of bacterial conjunctivitis market in Latin America, and Middle East and Africa in the near future.   

Choose License Type
Published Date:  Oct 2017
Category:  Pharmaceuticals
Report ID:   58751
Report Format:   PDF
Pages:   120
Rating:    4.1 (50)
Connect With Us
+1-408-641-3282
24/7 Research Support